Valera Pharmaceuticals Out-Licenses to Rights to Vantas

Valera Pharmaceuticals has entered into an agreement with BioPro Pharmaceutical (USA), based in San Francisco, Calif. This agreement provides BioPro with certain exclusive rights in the Asia-Pacific region to develop, distribute and sell Vantas, Valera's first product, a 12-month implant for the palliative treatment of advanced prostate cancer.

Yahoo News (http://biz.yahoo.com/bw/050228/285375_1.html)